HONG KONG, Oct 18, 2024 - (ACN Newswire via SeaPRwire.com) - CITIC Telecom International CPC Limited (“CITIC Telecom CPC”), a wholly-owned subsidiary of CITIC Telecom International Holdings Limited (SEHK: 1883) is at the forefront of AI+ innovation era, enabling dual empowerment of technology and data, and fostering a new business model of intelligence and innovation across industries. CITIC Telecom CPC has further unleashed multiple AI+ projects powered by “AI+ Cloud, Network, Security” framework, the integration of AI technology with big data analytics and security capabilities, and vital customer experience, fueling innovative AI+ applications across industries to reshape the Intelligence Operation Journey of enterprises.CITIC Telecom CPC collaborates with partners to co-create AI+ EcosystemFrom “Technology Empowerment”(+AI) to “Data Empowerment” (AI+)AI has become a cornerstone in today’s business landscape. As a leading Global-Local Intelligent DICT Service Partner, CITIC Telecom CPC fully embraces the global digitalization era and proactively deploys the visionary “ICT-MiiND” framework. This framework seamlessly integrates an “innovative” technology stack, the power of algorithms and big data into the ICT service platform, spanning across “Cloud, Network, Security” and bolstering the element of “intelligence” through cutting-edge AI technology and AIOps modules. CITIC Telecom CPC believes in the transformative power of AI+, actively enhances the in-depth integration of AI across various industries, driving innovative projects from focusing on "Big Data Modelling" to "Small-Scale Scenario implementation". CITIC Telecom CPC has not only deployed extensive resources in AI technologies, but also deeply integrated generative AI applications across the full-chain technology modules, evolving from Technology Empowerment (+AI) to Data Empowerment (AI+), ushering in a new era driven by AI algorithms and big data. AI+ covers diverse AI technologies and applications, integrating big data platforms with small-scale scenario models. This approach covers data collection, storage, governance and mining through deep algorithms, machine learning, and intelligent analysis, to develop a range of intelligent applications and AI+ solutions. Tailored to meet enterprise needs, it provides a one-stop service from business transformation to strategic analysis, efficiently fulfilling enterprise requirements.“CITIC Telecom CPC strives to integrate large AI models with diverse AI+ applications in small-scale scenarios, empowering customers to advance intelligent capabilities, unlocking a realm of new possibilities,” said Mr. Brook Wong, CEO of CITIC Telecom CPCMr. Brook Wong, Chief Executive Officer of CITIC Telecom CPC, said, “Striding from +AI to AI+, CITIC Telecom CPC pioneers AI technologies with a steadfast commitment to ‘Innovation Never Stops', continuously optimizes “Cloud, Network, Intelligence, Security” "solutions, and accelerates the development of intelligence-enabled industries. We actively dedicate various resources and collaborate with partners to co-create a prosperous AI+ ecosystem, enrich technical infrastructure, lead our team and the industry towards a generative AI era driven by large language models, AI technologies, data and intelligent analysis. We strive to integrate large AI models with diverse AI+ applications in small-scale scenarios, empowering customers to advance intelligent capabilities, unlocking a realm of new possibilities.”Transformative AI+ Solutions Generate New Driving Force for Data & Security ApplicationsCITIC Telecom CPC stands at the forefront of AI technology. With decades of ICT experience and industry expertise, its data science and innovation teams are propelling AI innovations with cutting-edge algorithms and deep learning techniques, unlocking data value and accumulating a range of generative AI applications for enterprises. The team has developed a series of award-winning and groundbreaking AI+ solutions such as the newly-launched AI Databank and AI Pentest, driving operational efficiency and cost savings for enterprises.AI Databank – Powering Big Data with Fast, Accurate & Actionable Insights on a Single PlatformAI Databank integrates tremendous data from various business systems, collecting a wide array of internal and external information (such as CRM and ERP). Utilizing generative AI technology, enhanced by deep learning and big data training, it enables efficient data management and real-time report generation. Users can interact with the platform to quickly retrieve data and multiple real-time data charts through dialog-based data queries, empowering data-driven decision making. AI Databank also analyzes current and historical data to build forecast models, helping companies in future planning.AI Pentest – Redefining Vulnerability Assessment with Proactive, Secure and Intelligent AutomationCITIC Telecom CPC has successfully led the Security Operations Center (SOC) to enter into a new AI-driven era since the launch of "TrustCSI™ 3.0" cybersecurity solution at the end of last year. The newly-launched AI Pentest plays a key role in the security portfolio. It is a lightweight solution powered by unique AI-driven bypass techniques to expose WAF vulnerabilities, enabling automated routine task scheduling to simplify the assessment of internal network asset and empower enterprises to keep pace with the rapidly changing IT environment. AI Pentest functions as an AI robot cleaner which automatically operates 24x7, helping enterprises identify key vulnerabilities in the network and establish a robust defense against potential threats.CITIC Telecom CPC's AI+ solutions have been implemented in various industries to foster integration of diverse AI+ applicationsAI+ Reshapes Industries with New Scenarios & Business ValuesCITIC Telecom CPC's AI+ solutions have been implemented in various industries to foster integration of diverse AI+ applications, assisting customers in incorporating generative AI technology, deep learning and data applications, empowering digital transformation for enterprises including:- AI+TelecommunicationsCITIC Telecom CPC leverages AI+ innovation capabilities to create a "Network and Information Security Threats Identification Algorithm Model". Leveraging Natural Language Processing (NLP), algorithm models and innovative technical architecture, an "AI+ telecommunications industry" application platform is created. The platform uses large AI security industry models to learn and identify scams as well as the patterns and characteristics of fraudulent calls. A repetitive learning and training cycle, integrated deep learning capability, on a large amount of known scams and fraudulent calls data is conducted to automatically identify new suspicious calls in the network immediately, greatly improving the accuracy of analysis and interception, and generating values for the society.Use case: Developed by CITIC Telecom, “AI+ Digital and Intelligent Cross-border Mobile Network Security Service Platform” project has won multiple distinguished awards in the market. The project utilizes Voice/Signaling/SMS firewall interception to help major telecommunications service providers, mobile service operators and enterprise sector to enable real-time alerts and interception of illegal and fraudulent Voice/SMS messages. The cloud-based platform can be utilized in local and cross-border cross-network scenarios to identify SMS messages from international countries to mainland China and inter-country communications. The solution effectively helps citizens identify registered SMS senders to stop fraudsters from sending scam SMS messages masquerading as other companies or organizations.- AI+ ManufacturingAs the global manufacturing industry is booming rapidly, the integration with different new technologies is accelerating. Powered by AI, enterprises actively deploy multiple AI tools, diverse application scenarios and big data to build an innovative digital and intelligence ecosystem. Industry chain not only enhances production efficiency and quality, but also responds to changes efficiently through digital planning and intelligent analysis, and also devises more precise future operations plans. AI-driven data security solutions provide enterprises with instant responses to security threats,enhanced data and cyber security, secure and intelligent manufacturing environment, elevating intelligent production to a new level.Use case: CITIC Dicastal, the first lighthouse factory in the global aluminum wheel industry, paved the way for its transformation journey with pivotal support from CITIC Telecom CPC and its subsidiary China Entercom in establishing a secure, efficient and fast data highway. This initiative enabled seamless connectivity among its global factories and significantly enhanced its digital and intelligent operational management capabilities. Leveraging its industry expertise, insights and technical knowledge, CITIC Telecom CPC’s Innovation team empowered CITIC Dicastal to overcome networking and security challenges across various application scenarios, including AI-driven manufacturing, process optimization, R&D design, operational decision-making, green and low-carbon initiatives, facilitating to build a “Vertical Industry Big Model of Aluminum Automobile Parts”, enhancing production efficiency and intelligence. CITIC Telecom CPC’s “AI+ Cloud, Network, Security” not only empowers the intelligent enhancement of CITIC Dicastal's entire industry chain but also reinforces its "AI+ Security" capabilities, refines real-time response alerts and develops interconnection across global factories while effectively monitoring information security threats. These initiatives strengthen the cornerstone of information security, forging a new era for the “Lighthouse Factory”. - AI+ AutomobileDemand forecasting is the most important part of the digital and intelligent transformation of an enterprise's supply chain. CITIC Telecom CPC's "Intelligent Order Demand Forecasting Solution" utilizes AI technology to predict complex and fragmented materials, improving the forecasting accuracy of order demand for vehicle models, and dynamically adjusting materials and production capacity planning.Use case: Headquartered in Europe, a world-renowned automobile parts supplier operates in 29 countries and regions, and serves various well-known automobile brands around the world. CITIC Telecom CPC’s "Intelligent Order Forecast Solution" enables customers to increase forecast accuracy to over 80%, optimize supply chain management, and achieve cost reduction and efficiency improvement.- AI+ RetailThe retail industry is undergoing a large-scale implementation of AI applications. CITIC Telecom CPC's “Cloud, Network, Intelligence, Security” integrated platform help enterprises build a secure, efficient and flexible digital infrastructure, enhance network transmission, information security, cloud computing resources and AI platform capabilities through dynamic perception, predictions and intelligent alerts for networks and applications. Harnessing AI technology and data analysis, we facilitate enterprises in expediting their digital transformation. By enhancing traditional workflow designs with scenario templates like customer service management, R&D evaluation, and marketing reports, strategically utilize big data to reinvent business to seize market opportunities.Use case: A world-renowned cosmetics retail brand has been committed to scientific research and innovation for many years. CITIC Telecom CPC's “AI+ Cloud, Network, Security” integrated platform helps to build a secure, efficient and flexible digital infrastructure. The dynamic perception of networks and applications, predictions and intelligent alerts for networks and applications assist the cosmetics retail brand to realize the values of “In Shanghai, For China, and Connect the World" to meet the needs of consumers in mainland China and around the world.To know more information aboutFrom “Technology Empowerment” (+AI) to “Data Empowerment” (AI+),please visit https://www.citictel-cpc.com/en-hk/ict-miindAbout CITIC Telecom CPCWe are CITIC Telecom International CPC Limited (“CITIC Telecom CPC”), a wholly-owned subsidiary of CITIC Telecom International Holdings Limited (SEHK: 1883), serving multinational enterprises the world over by addressing their specific ICT requirements with highly scalable tailored solutions built upon our flagship technology suites, comprising TrueCONNECT™ private network solutions, TrustCSI™ information security solutions, DataHOUSE™ cloud data center solutions, and SmartCLOUD™ cloud computing solutions.With the motto “Innovation Never Stops,” we leverage innovative technologies to boost technology empowerment (+AI). Embracing AI, AR, Big Data, IoT, and other cutting-edge emerging technologies we aim to unlock technical potential. By integrating deep learning and intelligent data analysis technologies, we transform these technologies into data empowerment (AI+) generative applications, reshaping the Intelligence Operation Journey of enterprises.With our Global-Local capabilities, we are committed to providing our customers with one-stop-shop ICT solutions with superior quality. Having a worldwide footprint across nearly 160 countries and regions, including Asia, Europe and America, Africa, the Middle East, and Central Asia, our global network resources connect nearly 170 points of presence (POPs), 60+ SDWAN gateways, 21 Cloud service centers, 30+ data centers, and three dedicated 24x7 Security Operations Centers (SOCs). We are certified with a series of international certifications, including SD-WAN Ready, ISO 9001, 14001, 20000, 27001, and 27017, to ensure our services compliance with international standards and resources for enterprises. We offer local professional services, superior delivery capabilities as well as exceptional customer experience and best practices through our global presence and extensive industry know-how, becoming a leading integrated intelligent ICT service provider to enterprise customers.For more information, please visit www.citictel-cpc.comMedia Contacts:Catherine YuenCITIC Telecom CPC(852) 2170 7536Email: catherine.yuen@citictel-cpc.com Copyright 2024 ACN Newswire via SeaPRwire.com.

香港, 2024年10月18日 - (亞太商訊 via SeaPRwire.com) - 中信國際電訊集團有限公司（「中信國際電訊」，香港交易所股份代號：1883）全資擁有的中信國際電訊(信息技術) 有限公司(「中信國際電訊CPC」) 站在AI+創新發展前沿，實現技術與數據雙賦能 ，推動產業鏈智能化升级新模式。中信國際電訊CPC進一步啟動多個人工智能+項目落地，透過智能化升級'智賦雲網安'底座；匯聚AI 技術、 大數據分析及信息安全交互能力，深入行業場景，融合智能應用賦能千行百業，重塑企業智能營運之旅。中信國際電訊CPC 攜手夥伴共築AI+ 生態圈從'技術賦能（+AI）'到'數據賦能（AI+）'人工智能(AI)在現今商業環境不可或缺，作為世界一流的數智通訊服務供應商，中信國際電訊CPC前瞻部署了面向未來的創新策略'ICT-MiiND / ICT-智賦'。更將'創新'技術、算力算法和大數據元素全棧無縫融合到ICT服務平台中，全面擁抱全球生成式AI時代，夯實智賦雲網安。中信國際電訊CPC深信AI+的變革力量，積極投入AI技術和AIOps模塊增强'智能'元素，聚焦從'大模型建設'到'小場景落地'能力，提升與各行業深度融合。中信國際電訊CPC不僅部署了豐富的AI技術資源，更通過深度整合生成式AI應用開發的全鏈條技術模塊、實踐由技術賦能(+AI )數智化應用模式，演化成數據賦能(AI+)新篇章。AI+不但涵蓋多元 AI 技術及應用，更融合大數據平台與小場景模型；從數據收集、儲存、治理、挖掘，通過深度算法、機器學習與智能分析，提煉出一系列數智應用場景與AI+ 解決方案。圍繞企業需求適配，提供從業務轉型到戰略解碼，再到運營提升的一站式服務，全方位滿足企業需求。中信國際電訊CPC行政總裁黃政華先生表示：「中信國際電訊 CPC致力將AI大模型與多元AI+應用小場景應用融合，助力客戶創增數智動能，實現更多可能！」中信國際電訊 CPC 行政總裁黃政華先生表示：「從+AI到AI+新模式，中信國際電訊 CPC作為業界AI技術先行者，一直秉持'創新‧不斷'研發多元智能技術，持續優化'雲網智安'解決方案，提速數智化賦能產業發展。我們積極投放資源，攜手夥伴共築繁榮AI+ 生態圈，豐富技術底座，引領客戶及行業走向以大語言模型，AI技術、智能分析及數據驅動的生成式AI年代；致力將AI大模型與多元AI+應用小場景應用融合，助力客戶創增數智動能，實現更多可能！」變革性的AI+解決方案 賦予數據及信息安全應用場景新動能中信國際電訊CPC站在AI技術的前沿，憑藉二十多年ICT的專業經驗和行業知識， 其數據科學和創新團隊在人工智能領域持續發力，以創新算法及深度學習技術釋放數據價值，更積累了大量生成式AI案例在企業端應用實踐，為企業降本增效。一系列屢獲殊榮的AI+解決方案中包括最新的AI Databank (智數庫)及AI Pentest (滲透測試)。- AI Databank (智數庫) - 大數據平台、智能化分析 | 更快、更準、更科學AI Databank (智數庫) 透過整合多個系統，收集內外信息 (如客服管理及營運日誌等)的海量數據，利用生成式AI技術，經過深度學習與大數據訓練，提供數據管理，即時生成報表。並可透過大型語言模型技術驅動的智慧分析功能，讓用戶以對話式界面與平台互動，快速檢索資料及生成各種可視化圖表，從而提煉數據驅動的商業價值。此外，更可通過分析當前及歷史數據，構建預測模版，助力企業規劃未來。- 革新自動AI Pentest (滲透測試)|更主動、更安全、更智能中信國際電訊CPC自去年底推出的'TrustCSI™ 3.0雲網神盾'網絡安全解決方案，成功引領安全運作中心(SOC)進入AI驅動的新時代。最新的AI Pentest滲透測試，更在整個方案中發揮關鍵作用。AI滲透測試是一項輕量級解決方案，採用獨特的 AI驅動技術，有效揭示網站應用程式防火牆(WAF)的弱點，並實現自動化的例行任務調度，以簡化內部網絡資產漏洞評估流程。AI滲透測試如同網絡AI掃地機器人，24x7全自動化運作，協助企業找出網絡中的關鍵漏洞，建立強大的主動式防禦機制 。中信國際電訊CPC的AI+方案落地於千行百業，推動AI+應用向多元場景發展AI+數智化產業新模式 為千行百業創優增值中信國際電訊CPC的AI+方案落地於千行百業，推動AI+應用向多元場景發展，協助産業鏈將生成式AI技術，深度學習及數據應用全棧融合業務，為企業數字化轉型之旅賦能，當中包括：- AI+電訊業中信國際電訊CPC以AI+創新能力打造「網絡與信息安全威脅識別算法模型」，憑藉自然語言處理，算法模型與創新技術架構，構建'AI+電訊產業'應用平台，利用人工智能安全行業大模型學習和識別騷擾，以及詐騙電話的模式與特徵 ，對大量已知騷擾及詐騙電話資料進行預學習，知識解構和深度訓練，自動學習識別網絡中即時出現新的騷擾或詐騙電話，大幅提高分析及攔截準確率，為社會締造價值。用戶個案: 中信國際電訊自主研發的'AI+跨境移動通信網絡安全管理平台'項目，獲得市場上多個重量級獎項。項目通過提供語音／信令/短信防火牆攔截，助力各主要電訊業界、流動服務營運商及企業客户實時預警及攔截非法欺詐語音／短信。平台採用雲端架構 ，應用於本地及跨境跨網場景，識別從國際到中國內地、國際與國際之間的通訊，方案有效協助市民識別已獲認證的短信發送人，以打擊涉及冒充其他公司或機構身分發出短信行騙。- AI+製造業製造業全球發展迅速，與新技術融合的動力與日俱增，在AI的引領下，企業積極綜合運用多種AI 工具、多元應用場景和大數據等創新技術，構建革新數智化生態系統。產業鏈不僅提高生産效率和質量，通過數字規劃和智能分析，能高效響應變化，並可更精準做好未來運營規劃。加持AI驅動信息安全解決方案，更為企業安全威脅監測提供即時回應，加強數據及信息安全保障，鍛造出更安全、更智能的製造環境，助力智能生産領域全面升級。用戶個案：中信戴卡是全球鋁車輪行業首家'燈塔工廠'，在其數智化建設過程中，中信國際電訊CPC聯同子公司中企通信扮演了至關重要的角色，為其搭建了安全、高效、快速的數據高速公路，網絡不僅覆蓋了廣泛的國際區域，還有效地促進了中信戴卡全球各工廠之間的互聯互通，並助力其顯著提升了數智化運營管理水平。創新團隊憑藉深厚的行業洞察與技術實力，助力中信戴卡在AI視覺賦能製造、AI賦能工藝優化、AI賦能研發設計、AI賦能營運決策、AI賦能綠色低碳等多個應用場景克服網絡和安全等方面的挑戰，助力構建'鋁製汽車零部件垂直行業大模型'，進一步提高了生產效率和智能化水平。智賦雲網安平台不僅為中信戴卡的全產業鏈智能升級提供了有力保障，更夯實了其AI+安全'能力，通過自動化威脅監測與高效實時的回應警報，築牢信息安全底座，鍛造'燈塔工廠'新輝煌。- AI+汽車業需求預測是企業供應鏈數字化、智能化轉型佈局中最重要的一環。中信國際電訊CPC'訂單需求智慧預測專案解決方案'，應用AI技術為零散物料供應鏈提供精準數據分析，提升車型訂單需求的預測準確率 ，動態調節物料及產能規劃。用戶個案：總部位于歐洲的世界知名的汽車零件供應商，業務分佈在29個國家地區，服務全球眾多知名汽車品牌。中信國際電訊CPC賦能客戶打造'訂單需求智慧預測專案解決方案'，提升預測準確率達80%以上，優化供應鏈管理， 實現降本增效。- AI+零售業零售業處於人工智能大規模落地應用水平。中信國際電訊CPC一體化'雲網智安'解决方案協助企業構建安全、高效及靈活的數智基礎設施，更透過對網絡及應用的動態感知、預測及智慧預警，提升網絡傳輸、信息安全、雲端運算資源及AI平台的能力。配合AI技術與數據分析助力企業提早數智化部署，在傳統工作流設計模式的基礎上增加場景模版，如客服管理、研發評審和營銷報告等場景，利用大數據規劃策略以贏得市場先機。用戶個案：國際知名化妝零售品牌多年來致力於科研與創新，憑藉中信國際電訊CPC'智賦雲網安'綜合方案，協助構建安全、高效及靈活的數字基建底座，通過對網絡及應用的動態感知、預測及智慧預警，助力實現「在上海、為中國、鏈全球」的優勢價值，滿足其中國內地以至世界各地消費者的需求。如欲了解更多有關從'技術賦能（+AI）'到'數據賦能（AI+）'，請瀏覽：https://www.citictel-cpc.com/zh-hk/ict-miind中信國際電訊CPC簡介中信國際電訊（信息技術）有限公司（「中信國際電訊CPC」）是中信國際電訊集團有限公司（香港交易所股份代號：1883）的全資附屬公司，一直矢志透過先進技術及旗艦解決方案，包括TrueCONNECT™專用網絡服務、TrustCSI™信息安全解決方案、DataHOUSE™全球統一雲數據中心解決方案及SmartCLOUD™雲端運算解決方案，為全球跨國企業提供綜合數碼解決方案， 滿足不同行業的ICT服務需求。憑借「創新‧不斷」的服務理念，中信國際電訊CPC積極利用創新技術，提煉'技術賦能'，將人工智能、擴增實境、大數據，物聯網和其他尖端新興技術，融合深度學習及智能數據分析技術，轉化為'數據賦能'生成式AI+應用，重塑企業智能營運之旅。中信國際電訊CPC以「服務在地，連接全球」的優勢，承諾為客戶提供最優質的一站式ICT服務。全球化網絡資源連接近170個服務據點、60多個SDWAN 網關；21個雲服務中心、30多個數據中心及3個全天候運作的安全運作中心，服務遍布约160個國家和地區，無縫連接亞洲、歐美、非洲、中東以及中亞等地區 。透過全球化服務佈局，多年不斷深耕各個行業與領域經驗，一系列國際認證（SD-WAN Ready, ISO 9001、14001、20000、27001 及27017），確保為企業提供國際化標準及專業在地服務能力，成為客戶信賴的信息智能化服務供應商。請瀏覽 www.citictel-cpc.com獲取更多資訊。傳媒查詢：Catherine Yuen中信國際電訊CPC(852) 2170 7536 電郵：catherine.yuen@citictel-cpc.com Copyright 2024 亞太商訊 via SeaPRwire.com.

ISTANBUL, October 18, 2024 - (ACN Newswire via SeaPRwire.com) - The 15th Turkish-Arab Economic Forum (TAFF 2024), aimed at deepening relations between Turkiye and the Gulf countries and defining joint strategies for the region, took place yesterday in Istanbul.The Forum saw the attendance of many key figures from the Gulf countries, including Kuwait's Minister of Finance Noora Suleiman Salem Al-Fassam, Iraq's Minister of Finance Taif Sami Mohammed, Egypt's Deputy Minister of Finance Ahmed Kouchouk, Tunisia's Minister of Economy and Planning Samir Abdelhafidh, Libya's Minister of Finance Dr Kalid Al-Mabrouk, President of the Turkish Investment Fund Baghdad Amreyev, Secretary General of the Egyptian Federation of Arab Chambers Dr Khaled Hanafy, Regional Director of the Saudi International Finance Corporation Fawaz Bilbeisi, Director of the World Bank GCC Cooperation Safaa El Tayeb El-Kogali, Partner at the UK's DWF Solomon Ebere, Board Member of the Qatar Chamber Mohamed Bin Ahmed Al Obaidly, and Vice President of International Business Development of the United Arab Emirates Khalid Al Marzooqi.Turkiye's Minister of Treasury and Finance Mehmet Simsek evaluated global and regional strategies.In his speech at the 15th Turkish-Arab Economic Forum, Minister of Treasury and Finance Mehmet Simsek highlighted the decline in inflation and the slowdown in monetary policies. He emphasized that global trade will continue in November, pointing out that while there are challenges, there are also opportunities in this process. Mehmet Simsek further noted that he expects an increase in cooperation across various sectors, emphasizing that partnerships in energy, manufacturing, technology, and machinery are crucial for realizing the region's potential and he expressed his support for diversification strategies.Dr. Erkan Kork stated that Turkiye and the Gulf countries could build a shared future.Speaking at the 15th Turkish-Arab Economic Forum, Dr. Erkan Kork, Chairman of the Board of BankPozitif, highlighted that the participating countries share the same geography, history, and values, and emphasized that joint steps would be stronger and more effective. He noted that building a shared future with the available know-how, technology, and investments is vital for unlocking the region's potential.BankPozitif Chairman Dr Erkan Kork at the 15th Turkish Arab Economic ForumExpressing pride in Turkiye's positioning as a fintech hub, Dr Erkan Kork predicted that Turkiye would play a leading role on the global stage in various fields in the near future. He also stressed the importance of forums, fairs and events like this for fostering relationships between the business world and governments of different countries.In his speech, Dr Erkan Kork pointed out that Turkiye is in a very strong position in terms of innovation and information technology, noting that while processing times in many sectors in Europe are long, they are much shorter in Turkiye. Dr. Erkan Kork also highlighted Turkiye's high level of competitiveness in recent years.At the forum, which had a high participation rate, Fatih Karahan, Governor of the Central Bank of the Republic of Turkiye, Burak Dagloglu, Member of the Board of Directors of the Turkiye Wealth Fund, and Rfat Hisarckloglu, President of the Union of Chambers and Commodity Exchanges of Turkiye, were also among the speakers.Source: BankPozitif, https://www.bankpozitif.com.trSait Inanc, +90533 722 49 69, info@bankpozitif.com.tr* This press release is issued through EuropeNewswire.Net (www.europenewswire.net) and distributed by EmailWire (www.emailwire.com) – the gloabal newswire that provide Press Release Distribution with Guaranteed Results™. Copyright 2024 ACN Newswire via SeaPRwire.com.

SHENZHEN, CHINA, Oct 18, 2024 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (the “Group” or “CMS”) is pleased to announce that on 18 October, the first batch of prescriptions of ruxolitinib phosphate cream (the “ruxolitinib cream” or the “Product”) for qualified vitiligo patients were issued in the Greater Bay Area, at Zhongshan Chen Xinghai Hospital of Integrated Traditional Chinese and Western Medicine, Foshan Fosun Chancheng Hospital, and Dongguan Songshan Lake Tungwah Hospital. The Product’s new drug application (NDA) was approved by the Pharmaceutical Administration Bureau (ISAF) of Macau on 11 April 2024, and subsequently the Product was approved by the Guangdong Provincial Medical Products Administration on August 19 through the "Hong Kong and Macau Medicine and Equipment Connect" policy, which officially introduced ruxolitinib cream for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age, providing a novel treatment option for patients with relevant indication into designated medical institutions in the Mainland of Greater Bay Area.In addition, on 24 September, the NDA for vitiligo indication of ruxolitinib cream has been accepted by the National Medical Products Administration of China (NMPA). In accordance with the relevant regulations of the drug real-world data application pilot program in the Hainan Boao Lecheng International Medical Tourism Pilot Zone (the “Pilot Zone”), CMS has conducted a real-world study on ruxolitinib cream in China. The results have shown positive efficacy, which is consistent with the key outcomes of global pivotal clinical studies. All secondary efficacy endpoints showed a trend of benefit consistent with the primary efficacy endpoint, and the treatment effect for vitiligo continued to improve with longer treatment duration. Meanwhile, through the safety monitoring data of the Pilot Zone, no new safety events have been identified. Adverse events mostly had severity levels of grade 1 or 2. No adverse event (AE) leading to discontinuation or withdrawal, and no serious adverse event (SAE) related to the study drug occurred.If the Product is successfully approved for marketing in Mainland China, it will be the first prescription drug approved by NMPA for repigmentation in vitiligo, bringing this novel treatment hopes for Chinese vitiligo patients.Furthermore, on 12 August 2023, the Product was approved by Hainan Medical Products Administration for Urgent Clinical Import, and officially became available to applicable patients in the Pilot Zone on August 18, for the topical treatment of non-segmental vitiligo in adults and adolescents aged 12 and above with facial involvement. Benefiting from the Early and Pilot Implementation Policy granted by the state to Hainan Free Trade Port and the Pilot Zone, patients with vitiligo in China can apply for the Product in Boao Super Hospital first and receive treatment from the expert team. As of 30 June 2024, more than 3,200 patients have been treated with ruxolitinib cream in Boao Super Hospital.CMS has always been patient-oriented and innovation-driven based on clinical needs, continuously striving to improve drug accessibility. Benefited from the "Hong Kong and Macau Medicine and Equipment Connect" policy, ruxolitinib cream was approved for use in the Greater Bay Area and completed its first batch of prescriptions, shortening the time difference for Chinese vitiligo patients to use innovative drug and benefiting more domestic patients. Looking forward to the future, the Group will continuously strive to meet the unmet needs of Chinese patients, continuously explore novel drugs with international quality, and efficiently promote products’ clinical development and commercialization, so as to bring more quality pharmaceutical products through differentiated innovation-breakthrough, to safeguard the health and life-quality of patients.About ruxolitinib creamRuxolitinib cream (Opzelura), a novel cream formulation of Incyte’s selective JAK1/JAK2 inhibitor ruxolitinib, is approved by the U.S. Food & Drug Administration for the topical treatment of nonsegmental vitiligo in patients 12 years of age and older. As of now, it is the first and only treatment for repigmentation approved for use in the United States[1]. Ruxolitinib cream (Opzelura) is also approved in the U.S. for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable[2]. In Europe, ruxolitinib cream (Opzelura) is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age[3].On 2 December 2022, the Group through a subsidiary of the Company, a dermatology medical aesthetic company (“CMS Skinhealth”) entered into a Collaboration and License Agreement (the “License Agreement”) with Incyte for topical formulations of ruxolitinib for the treatment of autoimmune and inflammatory dermatology diseases. In accordance with the License Agreement, the Group through CMS Skinhealth received an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (Indonesia, Philippines, Vietnam, Thailand, Myanmar, Malaysia, Cambodia, Laos, Singapore, Timor-Leste and Brunei Darussalam) (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The License Agreement commenced on its effective date and has a royalty term of ten years from the date of the commercial sale of the Product in the Territory (the “Royalty Term”). Upon the expiration of the Royalty Term, the License Agreement may be renewed for a period of ten years thereafter (the “Initial Extended Royalty Term”) as per certain conditions defined in the License Agreement. Upon the expiration of the Initial Extended Royalty Term, the License Agreement may be extended for a period otherwise agreed by both sides as per certain conditions defined in the License Agreement.Incyte has worldwide rights for the development and commercialization of the Product, marketed in the United States and Europe as Opzelura®. Opzelura and the Opzelura logo are registered trademarks of Incyte.About vitiligoVitiligo is a chronic autoimmune disease characterized by depigmentation of the skin, which results from the loss of pigment-producing cells known as melanocytes. It is estimated that there are approximately 14 million vitiligo patients in China[4]. Non-segmental vitiligo patients account for approximately 85% of them. Topical corticosteroids (TCS) and calcineurin inhibitors (CI) are used off-label for non-segmental vitiligo, however, these therapies have clinical deficiencies with long-term adverse reactions of long-term treatment or limited efficacy[5,6].About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries. While strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology business, CMS independently operates its dermatology and medical aesthetics business, and ophthalmology business, aiming to gain leading positions in specialty therapeutic fields, whilst enhancing the scale and efficiency. At the same time, CMS has expanded its business territory to the Southeast Asian market, striving to become a "bridgehead" for global pharmaceutical companies to enter the Southeast Asian market, further escorting the sustainable and healthy development of the Group.Reference:1. Drug approval information can be found on the FDA official website, as follows: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-topical-treatment-addressing-repigmentation-vitiligo-patients-aged-12-and-older2. Drug approval information can be found on the Incyte official website, as follows: https://investor.incyte.com/news-releases/news-release-details/incyte-announces-us-fda-approval-opzeluratm-ruxolitinib-cream3. Drug approval information can be found on the EMA official website, as follows: https://www.ema.europa.eu/en/medicines/human/EPAR/opzelura4. Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet. 2015;386(9988):74-84. doi:10.1016/S0140-6736(14)60763-75. Consensus on the diagnosis and treatment of vitiligo (2021 version)6. Kubelis-López DE, Zapata-Salazar NA, Said-Fernández SL, Sánchez-Domínguez CN, Salinas-Santander MA, Martínez-Rodríguez HG, Vázquez-Martínez OT, Wollina U, Lotti T, Ocampo-Candiani J. Updates and new medical treatments for vitiligo (Review). Exp Ther Med. 2021 Aug;22(2):797. doi: 10.3892/etm.2021.10229. Epub 2021 May 25. PMID: 34093753; PMCID: PMC8170669.CMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactChina Medical System Holdings Ltd.CMS Investor RelationsWebsite: https://web.cms.net.cn/en/home/Source: China Medical System Holdings Ltd. Copyright 2024 ACN Newswire via SeaPRwire.com.

深圳, 2024年10月18日 - (亞太商訊 via SeaPRwire.com) - 康哲藥業控股有限公司（「康哲藥業」）欣然宣佈，磷酸蘆可替尼乳膏（「蘆可替尼乳膏」或「產品」）在中山陳星海中西醫結合醫院、佛山複星禪誠醫院、以及東莞松山湖東華醫院為符合條件的白癜風患者開出大灣區首批處方。產品於2024年4月11日獲得澳門政府藥物監督管理局（ISAF）批准新藥上市申請，隨後通過「港澳藥械通」政策，並於8月19日獲得廣東省藥品監督管理局批准，正式落地粵港澳大灣區內地指定醫療機構，用於12歲及以上青少年和成人患者伴面部受累的非節段型白癜風的治療，為相關適應症患者提供了全新治療選擇。此外，蘆可替尼乳膏白癜風適應症新藥上市許可申請已於9月24日獲得中國國家藥品監督管理局（NMPA）受理。根據海南博鰲樂城國際醫療旅遊先行區藥品真實世界數據應用試點程式有關規定，蘆可替尼乳膏在中國開展真實世界研究，療效積極，與境外關鍵臨床研究結果一致。所有的次要療效指標均顯示出與主要療效指標一致的獲益趨勢，且治療時間越長，患者的白癜風治療效果持續改善。同時利用了樂城先行區安全監測數據，未發現新的安全性事件。不良反應的嚴重程度大部分均為1級或2級，未發生導致停藥或退出的不良事件（AE），未發生研究藥物相關的嚴重不良事件（SAE）。若產品於中國大陸獲批上市，其有望成為首個經NMPA批准用於白癜風複色的處方藥，將為中國廣大白癜風患者帶來治療新曙光。除上述進展外，產品此前於2023年8月12日獲得海南省藥監局批準臨床急需進口，並於8月18日正式落地海南博鰲樂城國際醫療旅遊先行區，用於12歲及以上青少年和成人患者伴面部受累的非節段型白癜風的局部治療。受益于國家賦予海南自由貿易港、博鰲樂城國際醫療旅遊先行區「先行先試」特許政策，中國白癜風患者可在博鰲超級醫院先行申請使用產品並接受專家團隊的治療。截至2024年6月30日，已有超3,200例患者在博鰲超級醫院使用蘆可替尼乳膏進行治療。康哲藥業始終以患者為中心，以臨床需求驅動創新，為提升藥物可及性而持續努力。本次蘆可替尼乳膏得益於「港澳藥械通」政策支持，先行獲批引入大灣區，並完成首批處方落地，縮短了中國白癜風患者使用創新藥的用藥時差，讓更多國內白癜風患者獲益。展望未來，康哲藥業將繼續為滿足中國患者未盡之需而奮進，持續挖掘國際品質的新藥、好藥，高效推動產品臨床開發和商業化發展，以差異化的創新突破為病患帶來更多優質的醫藥產品，為守護患者健康生活和生命質量貢獻力量。關於蘆可替尼乳膏蘆可替尼乳膏（Opzelura），為Incyte的JAK1/JAK2選擇性抑制劑蘆可替尼的創新乳膏製劑，已獲得美國食品和藥物管理局（FDA）批準用於12歲及以上非節段型白癜風患者的局部治療。截至目前，蘆可替尼乳膏是首個也是唯一一種在美國獲批使用的白癜風複色產品[1]。此外，產品在美國獲批用於傳統外用處方療法不可取或不能充分控制病情之12歲及以上非免疫功能低下的輕中度AD患者的局部短期和非持續性慢性治療[2]。產品也於歐洲獲批用於12歲及以上青少年及成人患者伴面部受累的非節段型白癜風的治療[3]。康哲藥業於2022年12月2日，通過其附屬公司-康哲美麗與Incyte就用於治療自身免疫性炎症皮膚病的蘆可替尼乳膏製劑訂立合作和許可協議（「許可協議」）。根據該等許可協議，康哲藥業通過康哲美麗獲得在中國大陸、香港特別行政區、澳門特別行政區、台灣地區及東南亞十一國（印尼、菲律賓、越南、泰國、緬甸、馬來西亞、柬埔寨、老撾、新加坡、東帝汶以及文萊）（「區域」）開發、註冊及商業化產品的獨家許可權利，以及在區域內生產產品的非獨家許可權利。許可協議期限開始於許可協議生效日，自產品在區域內首次商業化銷售之日起擁有十年的授權期限（「授權期限」）。授權期限屆滿後，根據許可協議約定的特定條件，許可協議期限可延長十年（「初始延展授權期限」）。初始延展授權期限屆滿後，根據許可協議約定的特定條件，雙方可另行協商許可協議的延長期限。Incyte擁有產品的全球開發和商業化權利，產品在美國及歐洲以Opzelura®的名稱銷售。Opzelura及其logo為Incyte的注冊商標。關於白癜風白癜風是一種慢性自身免疫性疾病，其特徵是皮膚色素脫失，其發病原因為產生色素的細胞即黑素細胞的缺失。據估算，中國白癜風患者約1,400萬[4]。白癜風患者中約85%為非節段型白癜風。外用皮質類固醇（TCS）及鈣調神經磷酸酶抑制劑（CI）均為非節段型白癜風的標籤外用藥，然而，這些現有外用藥物療法有長期用藥的不良反應或療效有限的臨床痛點[5、6]。關於康哲藥業康哲藥業是一家鏈接醫藥創新與商業化，把控產品全生命週期管理的開放式平台型企業，致力於提供有競爭力的產品和服務，滿足尚未滿足的醫療需求。康哲藥業專注於全球首創（FIC）及同類最優（BIC）的創新產品，並高效推進創新產品臨床研究開發和商業化進程，賦能科研成果向診療實踐的持續轉化，造福患者。康哲藥業聚焦專科領域，擁有被驗證的商業化能力，廣泛的渠道覆蓋和多疾病領域專家資源，核心在售產品已獲領先的學術與市場地位。康哲藥業圍繞優勢專科領域不斷縱深發展，以鞏固心腦血管/消化業務競爭力，並將皮膚醫美、眼科業務獨立運營，培育專科小領域的大龍頭，提升專科規模效率。同時業務版圖拓展至東南亞市場，著力成為全球藥企進軍東南亞市場的「橋頭堡」，助力康哲藥業高品質持續健康發展。參考文獻/資料：1、FDA批準信息可在FDA官網查詢，網址：https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-topical-treatment-addressing-repigmentation-vitiligo-patients-aged-12-and-older2、FDA批準信息可在incyte官網查詢，網址：https://investor.incyte.com/news-releases/news-release-details/incyte-announces-us-fda-approval-opzeluratm-ruxolitinib-cream3、EMA批準信息可在EMA官網查詢，網址：https://www.ema.europa.eu/en/medicines/human/EPAR/opzelura4、Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet. 2015;386(9988):74-84. doi:10.1016/S0140-6736(14)60763-75、《白癜風診療共識（2021版）》6、Kubelis-Lopez DE, Zapata-Salazar NA, Said-Fernandez SL, Sanchez-Dominguez CN, Salinas-Santander MA, Martinez-Rodriguez HG, Vazquez-Martinez OT, Wollina U, Lotti T, Ocampo-Candiani J. Updates and new medical treatments for vitiligo (Review). Exp Ther Med. 2021 Aug;22(2):797. doi: 10.3892/etm.2021.10229. Epub 2021 May 25. PMID: 34093753; PMCID: PMC8170669.康哲藥業免責與前瞻性聲明本新聞無意向您做任何產品的推廣，非廣告用途。本新聞不對任何藥品和醫療器械和/或適應症作推薦。若您想瞭解具體疾病診療信息，請遵從醫生或其他醫療衛生專業人士的意見或指導。醫療衛生專業人士作出的任何與治療有關的決定應根據患者的具體情況並遵照藥品說明書。由康哲藥業編制的此新聞不構成購買或認購任何證券的任何要約或邀請，不形成任何合約或任何其他約束性承諾的依據或加以依賴。本新聞由康哲藥業根據其認為可靠之資料及數據編制，但康哲藥業並無進行任何說明或保證、明述或暗示，或其他表述，對本新聞內容的真實性、準確性、完整性、公平性及合理性不應加以依賴。本新聞中討論的若干事宜可能包含涉及康哲藥業的市場機會及業務前景的陳述，該等陳述分別或統稱為前瞻性聲明。該等前瞻性聲明並非對未來表現的保證，存在已知及未知的風險、不明朗性及難以預知的假設。康哲藥業並不採納本新聞包含的第三方所做的任何前瞻性聲明及預測，康哲藥業對該等第三方聲明及預測不承擔責任。 Copyright 2024 亞太商訊 via SeaPRwire.com.